Compare SQNS & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | ATYR |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | France | United States |
| Employees | N/A | 58 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4M | 51.7M |
| IPO Year | 2011 | N/A |
| Metric | SQNS | ATYR |
|---|---|---|
| Price | $3.15 | $0.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $20.33 | $3.67 |
| AVG Volume (30 Days) | 69.3K | ★ 2.2M |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $49.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.40 |
| 52 Week High | $10.93 | $7.29 |
| Indicator | SQNS | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 43.42 |
| Support Level | $2.86 | $0.43 |
| Resistance Level | $3.27 | $0.86 |
| Average True Range (ATR) | 0.23 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 35.82 | 0.05 |
Sequans Communications SA is a fabless semiconductor company specializing in wireless 4G and 5G cellular technologies for the Internet of Things (IoT). Sequans' engineers design and develop, secure, and energy-efficient semiconductor solutions that enable the next generation of AI-connected applications, including smart energy metering, industrial automation, smart mobility and logistics, secure payments, e-health, and smart home solutions. The Company offers a comprehensive portfolio of wireless connectivity solutions, including radio frequency (RF) transceivers, integrated circuits (ICs) for baseband processing, as well as modules, software, & protocol stacks. The Company has one operating segment, which is the design & marketing of semiconductor components for cellular wireless systems.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).